New hope for relapsed leukemia: Triple-Drug attack shows promise
NCT ID NCT07563179
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This study tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) in adults with a type of leukemia (AML) that has come back or not responded to standard treatment. The goal is to see if this combo can wipe out hidden cancer cells and keep patients in remission longer. About 10 participants will receive the treatment in cycles, with close monitoring for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen University general hospital
RECRUITINGShenzhen, Guangdong, 0755, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.